Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.

吉林省輝南長龍生化藥業股份有限公司

Jilin Province Huinan Changlong Bio-pharmacy Company Limited

(a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 8049)

ANNOUNCEMENT AND NOTICE OF ANNUAL GENERAL MEETING

SUMMARY

The board of directors of the Company (the "Board") has been notified that, with effect from 9 June 2026, Mr. Zhang Hong, Mr. Zhang Xiao Guang, Mr. Zhao Bao Gang, and Mr. Wu Guo Wen intend to resign as executive directors, and Ms. Qiao Xiao Chun intends to resign as a supervisor, due to reaching their retirement age. The above resignations will officially take effect upon the approval of the appointment of the new personnel at the annual general meeting of the Company.

The Board announces that the Company is scheduled to hold its annual general meeting on 9 June 2026, at which ordinary resolutions will be proposed for the shareholders of the Company to consider and approve the appointment of Mr. Wang Wei, Ms. Chi Chun Hong, and Ms. Li Ning as executive directors of the Company, and the appointment of Mr. Zhang Biao as a supervisor of the Company.

The board of directors (the "Board") of Jilin Province Huinan Changlong Bio-pharmacy Company Limited (the "Company") hereby announces that Mr. Zhang Hong, Mr. Zhang Xiao Guang, Mr. Zhao Bao Gang, and Mr. Wu Guo Wen have submitted their resignations as they have reached retirement age. They intend to resign as executive directors of the Company with effect from 9 June 2026, subject to the consideration and approval of the appointment of the new directors at the Annual General Meeting. Among them, Mr. Zhang Hong will simultaneously resign as an authorized representative and a member of the Remuneration Committee of the Company; Mr. Zhang Xiao Guang will simultaneously resign as a member of the Nomination Committee of the Company; and Mr. Zhao Bao Gang will simultaneously resign as an authorized representative of the Company. In addition, Ms. Qiao Xiaochun has also submitted her resignation due to retirement and intends to resign as a supervisor of the Company with effect from 9 June 2026, subject to the consideration and approval of the appointment of the new supervisor at the Annual General Meeting.

Mr. Zhang Hong, Mr. Zhang Xiao Guang, Mr. Zhao Bao Gang, and Mr. Wu Guo Wen have confirmed that they have no disagreement with the Board and there are no other matters relating to their resignations that need to be brought to the attention of the shareholders of the Company.

In addition to the aforementioned persons intending to retire and resign, two current executive directors, Mr. Zhang Yi and Mr. Xu Xiang Fu, three independent non-executive directors, Mr. Gao Qi Pin, Mr. Bai Jun Gui, and Ms. Tian Jie, and two supervisors, Mr. Yan Li Yu and Mr. Wang Ying Xu, will offer themselves for re-election at this Annual General Meeting.

The Board announces that the Company is scheduled to hold an Annual General Meeting on 9 June 2026, at which ordinary resolutions will be proposed for the shareholders of the Company to approve the appointments of Mr. Wang Wei, Ms. Chi Chun Hong and Ms. Li Ning as executive directors of the Company, and Mr. Zhang Biao as a supervisor of the Company. For detailed information on the director and supervisor candidates, please refer to Appendix II.

NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that the annual general meeting of Jilin Province Huinan Changlong Bio-pharmacy Company Limited ("the Company") for the year ended 31 December 2025 (the "AGM") will be held at Economic Development Zone, Chaoyang Town, Huinan County, Tonghua, Jilin Province (吉林省通化市輝南縣朝陽鎮經濟開發區), the People's Republic of China (the "PRC") on Tuesday, 9 June 2026 at 10:00 a.m. for the following purposes:

As ordinary resolutions:

1. to receive and consider the audited consolidated financial statements of the Company and the reports of the Directors of the Company and the independent auditor's report of the Company for the year ended 31 December 2025;

2. to consider and approve the report of the Supervisory Committee of the Company for the year ended 31 December 2025;

3. to consider the reappointment of Prism Hong Kong Limited as auditors of the Company for the year ending 31 December 2026 and authorize the Directors to fix their remuneration;

4. to consider and approve the remuneration proposals for Directors and supervisors of the Company for the year ending 31 December 2026;

5. to re-elect the directors of the ninth session of the Board for a term of three years commencing from 9 June 2026, until the date of the Annual General Meeting to be held in 2029, and to authorize the Board to fix their remuneration (for details of the director candidates, please refer to Appendix I):

   (a) to re-elect Mr. Zhang Yi as an executive director;

   (b) to re-elect Mr. Xu Xiang Fu as an executive director;

   (c) to re-elect Mr. Gao Qi Pin as an independent non-executive director;

   (d) to re-elect Mr. Bai Jun Gui as an independent non-executive director; and

   (e) to re-elect Ms. Tian Jie as an independent non-executive director;

6. to re-elect the supervisors of the ninth session of the Supervisory Committee of the Company for a term of three years commencing from 9 June 2026, until the date of the Annual General Meeting to be held in 2029, and to authorize the Board to fix their remuneration:

   (a) to re-elect Mr. Yan Li Yu as a supervisor; and

   (b) to re-elect Mr. Wang Ying Xu as a supervisor;

7. to consider and approve the election and appointment of Mr. Wang Wei as an executive director of the Board for a term of three years commencing from 9 June 2026, until the date of the Annual General Meeting to be held in 2029, and to authorize the Board to fix his remuneration (for details of the director candidates, please refer to Appendix II);

8. to consider and approve the election and appointment of Ms. Chi Chun Hong as an executive director of the Board for a term of three years commencing from 9 June 2026, until the date of the Annual General Meeting to be held in 2029, and to authorize the Board to fix her remuneration (for details of the director candidates, please refer to Appendix II);

9. to consider and approve the election and appointment of Ms. Li Ning as an executive director of the Board for a term of three years commencing from 9 June 2026, until the date of the Annual General Meeting to be held in 2029, and to authorize the Board to fix her remuneration (for details of the director candidates, please refer to Appendix II);

10. to consider and approve the election and appointment of Mr. Zhang Biao as a supervisor of the Company for a term of three years commencing from 9 June 2026, until the date of the Annual General Meeting to be held in 2029, and to authorize the Board to fix his remuneration (for details of the supervisor candidates, please refer to Appendix II).

As special resolution:

1. to consider and if the right fit, pass with or without modifications, the following resolution as a special resolution:

   "**THAT**:

   (a) subject to paragraphs (c), (d) and (e) below, the exercise by the Board of Directors of the Company (the "Board") during the Relevant Period (as defined in paragraph (f) below) of all the powers of the Company separately or concurrently to allot, issue and deal with domestic shares of nominal value of RMB0.10 each in the share capital of the Company (the "Domestic Shares") and/or overseas-listed foreign shares of nominal value of RMB0.10 each in the share capital of the Company (the "H Shares") be and is hereby approved;

   (b) the approval in paragraph (a) above shall authorise the Board to make an offer or agreement or grant an option during the Relevant Period which would or might require Domestic Shares and/or H Shares to be allotted and issued either during or after the end of the Relevant Period;

   (c) the aggregate nominal value of Domestic Shares to be allotted and issued or agreed to be allotted and issued (whether pursuant to an option or otherwise) by the Board pursuant to the approval in paragraphs (a) and (b) above, otherwise than pursuant to (i) a rights issue (as defined in paragraph (f) below); (ii) the exercise of the conversion rights under the terms of any securities which are convertible into such shares; (iii) the exercise of rights of subscription under the terms of any warrants issued by the Company; or (iv) any scrip dividend or similar arrangement providing for the allotment of such shares in lieu of the whole or part of a dividend on such shares in accordance with the articles of association of the Company, shall not exceed 20 per cent. of the aggregate nominal value of the Domestic Shares then in issue at the date of the passing of this resolution;

   (d) the aggregate nominal value of H Shares to be allotted and issued or agreed to be allotted and issued (whether pursuant to an option or otherwise) by the Board pursuant to the approval in paragraphs (a) and (b) above, otherwise than pursuant to (i) a rights issue (as defined in paragraph (f) below); (ii) the exercise of the conversion rights under the terms of any securities which are convertible into such shares; (iii) the exercise of rights of subscription under the terms of any warrants issued by the Company; or (iv) any scrip dividend or similar arrangement providing for the allotment of such shares in lieu of the whole or part of a dividend on such shares in accordance with the articles of association of the Company, shall not exceed 20 per cent. of the aggregate nominal value of the H Shares then in issue at the date of the passing of this resolution;

(e) the approval in paragraph (a) above shall be conditional upon the approval of the China Securities Regulatory Commission being obtained by the Company;

(f) for the purpose of this special resolution:

"Relevant Period" means the period from the passing of this special resolution until whichever is the earlier of:

(i) the conclusion of the next annual general meeting of the Company following the passing of this special resolution;

(ii) the expiration of a period of 12 months following the passing of this special resolution; or

(iii) the date on which the authority set out in this special resolution is revoked or varied by a special resolution of the members of the Company in general meeting.

"Rights Issue" means an offer of shares open for a period fixed by the Directors to holders of shares of the Company on the register of members of the Company on a fixed record date and, where appropriate, the holders of the other equity securities of the Company entitled to be offered therein, in proportion to their then holdings of such shares or other equity securities (subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of any relevant jurisdiction, or the requirements of any regulatory body or any stock exchange);

(g) the Board be and is hereby authorised to make such amendments to the articles of association of the Company as it thinks fit so as to increase the registered share capital and to reflect the new capital structure of the Company as a result of the allotment and issue of shares of the Company pursuant to the approval granted under paragraph (a) above".

2. to transact any other business.

By order of the Board of
Jilin Province Huinan Changlong Bio-pharmacy Company Limited
Zhang Hong
Chairman

Tonghua, Jilin Province, the PRC
24 April 2026

Notes:

1. Any shareholder of the Company entitled to attend and vote at the meeting mentioned above is entitled to appoint one or more proxies to attend and vote at the meeting on his or her behalf in accordance with the articles of association of the Company. A proxy needs not be a shareholder of the Company.

2. In order to be valid, a proxy form of holder of H shares and, if such proxy form is signed by a person under a power of attorney or other authority on behalf of the appointer, a notarially certified copy of that power of attorney or authority shall be deposited at the Computershare Hong Kong Investor Services Limited on Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Hong Kong ("the Company's Shares Registrar") not less than 24 hours before the time for holding the meeting or 24 hours before the time appointed for taking the poll.

3. In order to be valid, a proxy form of holder of Domestic shares and, if such proxy form is signed by a person under a power of attorney or other authority on behalf of the appointer, a notarially certified copy of that power of attorney or authority shall be deposited at the Registered Address of the Company not less than 24 hours before the time for holding the meeting or 24 hours before the time appointed for taking the poll.

4. Shareholders of the Company or their proxies shall produce documents of their proof of identity when attending the meeting.

5. The register of shareholders of the Company will be closed from 11 May 2026 to 9 June 2026 (both days inclusive), during which no transfer of shares will be registered. As regards holders of H Shares and in order to ascertain the entitlement to attendance at the above meeting, all properly completed transfer forms accompanied by the relevant share certificate must be lodged with the Company's Share Registrar not later than 8 May 2026 before 4:30 p.m. for registration.

6. Shareholders of the Company who intend to attend the AGM have to notify in writing of their attendance by sending such notice to the Company by hand, post or fax not later than 19 May 2026.

7. The purpose of having special resolution number 1 it to grant a general power to the board of directors to allot and issue new shares subject to applicable laws, regulations and rules.

8. The AGM is expected to last for half a day. Shareholders and their proxies attending the AGM are responsible for their own transportation and accommodation expenses.

9. Registered Address of the Company and the contact details of the Company are as follows:

   31 Beishan Street, Chaoyang Town, Huinan County,
   Tonghua, Jilin Province, the PRC
   Fax no: 86 (435) 8212738

For the biographical details of the director and supervisor candidates, please refer to the "Biographical Details of Directors and Senior Management" section in the Company's 2025 Annual Report. All candidates for re-election as directors are currently directors of the eighth session of the Board of the Company, and all candidates for re-election as supervisors are currently supervisors of the eighth session of the Supervisory Committee of the Company.

The remuneration payable to the directors and supervisors is determined by the Remuneration Committee with reference to their respective time commitment, contributions, and skill levels in the Company's affairs, specifically as follows:

(a) All re-elected directors and supervisors are not entitled to any director's or supervisor's fee, but may receive remuneration in accordance with their respective duties;

(b) In addition to the above salary, each director and supervisor may receive an annual incentive bonus, the amount of which is determined by the Remuneration Committee with reference to the Group's profitability and market conditions.

Upon approval of the above Ordinary Resolution No. 5, all re-elected directors will enter into a director's service contract with the Company for a term of three years, commencing from 9 June 2026, until the date of the Annual General Meeting to be held in 2029.

Upon approval of the above Ordinary Resolution No. 6, all re-elected supervisors will enter into a service contract with the Company for a term of three years, commencing from 9 June 2026, until the date of the Annual General Meeting to be held in 2029.

For the interests of the director and supervisor candidates in the shares of the Company (as defined in Part XV of the Securities and Futures Ordinance), please refer to the paragraph headed "Directors' and Supervisors' Interests in Shares" in the Report of the Directors contained in the Company's 2025 Annual Report.

The directors believe that, regarding the election of the eighth session of directors and supervisors, there are no other matters that need to be brought to the attention of the directors of the Company other than those set out above. Save as disclosed above, there is no other information required to be disclosed pursuant to any of the requirements under Rule 17.50(2) of the GEM Listing Rules (particularly in relation to sub-paragraphs (g) to (v) thereof).

Mr. Wang Wei (Candidate for Executive Director)

Executive Director (Nominated), Deputy General Manager, Sales Director, male, aged 40, holds a bachelor's degree. He graduated from Changchun University of Science and Technology majoring in Biotechnology, and holds a Master's degree in Economics and Management from Peking University HSBC Business School. He has been working at Jilin Province Huinan Changlong Bio-pharmacy Company Limited since 2021 and is currently the Sales Director of the Company. He possesses a solid foundation in biotechnology and an educational background in economics and management, with extensive experience in pharmaceutical industry market operations, marketing system construction, and team management. Since taking office, he has led the establishment of a comprehensive sales management system, coordinating market expansion, academic research, channel construction, and brand promotion, demonstrating strong operational management capabilities, market judgment, and overall coordination skills.

He has not held any directorship in any public listed companies in the past three years, and he does not have any relationship with any directors, senior management, substantial shareholders, or controlling shareholders of the Company. Within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), he does not have any interests in the shares of the Company.

Ms. Chi Chun Hong (Candidate for Executive Director)

Executive Director (Nominated), Minister of Finance Department, female, aged 48, holds a university degree. She graduated from the Party School of the Jilin Provincial Committee majoring in Business Administration and is an assistant economist. She has been working at Jilin Province Huinan Changlong Bio-pharmacy Company Limited since 1995, deeply engaged in the financial field of the pharmaceutical industry for more than 30 years. She has successively held key financial positions in the Company, possessing a solid professional foundation and rich experience in the financial management of listed companies. She is currently the Minister of the Finance Department of the Company, comprehensively presiding over financial accounting, budget management, fund control, cost optimization, internal control compliance, and financial report disclosure. She was previously awarded the honorary title of Advanced Accountant of Jilin Province.

She has not held any directorship in any public listed companies in the past three years, and she does not have any relationship with any directors, senior management, substantial shareholders, or controlling shareholders of the Company. Within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), she does not have any interests in the shares of the Company.

Ms. Li Ning (Candidate for Executive Director)

Executive Director (Nominated), Minister of Production Management Department, Director of GMP Office, female, aged 43, holds a bachelor's degree. She graduated from Changchun University of Chinese Medicine majoring in Pharmaceutical Engineering, and is a licensed pharmacist and senior engineer. She has been working at Jilin Province Huinan Changlong Bio-pharmacy Company Limited since 2013, deeply engaged in the field of pharmaceutical production management for many years. She is currently the Minister of the Production Management Department of the Company, fully responsible for overall production planning, GMP compliance management, capacity optimization and enhancement, and safety production management. She has a solid foundation in pharmaceutical expertise and rich experience in production operations management. With outstanding professional and technical capabilities, she has been deeply involved in core product research and development and technical upgrades. In 2016, as a key member participating in the development and application project of Haikun Shenxi Capsules, she was awarded the second prize of the Jilin Province Science and Technology Award.

She has not held any directorship in any public listed companies in the past three years, and she does not have any relationship with any directors, senior management, substantial shareholders, or controlling shareholders of the Company. Within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), she does not have any interests in the shares of the Company.

Mr. Zhang Biao (Candidate for Supervisor)

Supervisor (Nominated), Quality Manager, Mr. Zhang Biao, male, aged 44, holds a bachelor's degree. He graduated from Changchun University of Chinese Medicine majoring in Pharmaceutical Engineering, and is a licensed pharmacist and junior engineer. From 2015 to 2018, he worked at Jilin Province Huinan Changlong Bio-pharmacy Company Limited as the Minister of the Quality Assurance Department; since 2019, he has been the person in charge of quality for the Company. He has long been deeply engaged in the frontline of pharmaceutical quality manager, comprehensively coordinating the construction of the pharmaceutical quality system, quality control, quality assurance, and compliance management. He has strong principles, upright professional ethics, and an outstanding sense of responsibility. He is familiar with pharmaceutical industry regulatory policies and the governance requirements of listed companies, possessing excellent risk control capabilities and supervisory management qualities.

As at the date of this notice, the Board comprises six executive directors, being Zhang Hong, Zhang Xiao Guang, Zhao Bao Gang, Wu Guo Wen, Zhang Yi and Xu Xiang Fu and three independent non-executive directors, being Gao Qi Pin, Bai Jun Gui and Tian Jie.

This notice will remain on the "Latest Listed Company Announcements" page on the Stock Exchange website at www.hkexnews.hk for at least 7 days from the date of its posting.